Zobrazeno 1 - 10
of 907
pro vyhledávání: '"FOLFOXIRI"'
Autor:
Wenwei Yang, Dong Chen, Yaru Niu, Guifu Wu, Zhangkan Huang, Xinyu Bi, Hong Zhao, Xu Che, Yongkun Sun
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeTo explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).Patients and methodsThis was a dual-center, phase II trial
Externí odkaz:
https://doaj.org/article/a474726aa473498b8d391eb6fa0e5cff
Autor:
Wen Zhang, Haitao Zhou, Jun Jiang, Yuelu Zhu, Shuangmei Zou, Liming Jiang, Yuan Tang, Jianwei Liang, Yongkun Sun, Zhichao Jiang, Wang Qu, Ying Li, Aiping Zhou
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Purpose Chemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to evaluate the efficacy and safety of neoadjuvant triplet chemotherapy with mFOLFOXIRI (folin
Externí odkaz:
https://doaj.org/article/75ea248036bf4ce0aa752d7f0bcc0e73
Autor:
Shenglin Li, Long Yuan, Mengying Yue, Yuan Xu, Suwei Liu, Feng Wang, Xiaoqin Liu, Fengyan Wang, Juan Deng, Qiu Sun, Xianwang Liu, Caiqiang Xue, Ting Lu, Wenjuan Zhang, Junlin Zhou
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Purpose Early evaluation of the efficacy of first-line chemotherapy combined with bevacizumab in patients with colorectal cancer liver metastasis (CRLM) remains challenging. This study used 2-month post-chemotherapy spectral computed tomogra
Externí odkaz:
https://doaj.org/article/4da1945126634477be524cd3c82731c8
Autor:
Yi-Hsin Liang, Jin-Tung Liang, Ben-Ren Lin, John Huang, Ji-Shiang Hung, Shuo-Lun Lai, Tzu-Chun Chen, Jia-Huei Tsai, Yung-Ming Cheng, Ting-Han Tsao, Wen-Ling Hsu, Kuo-Hsing Chen, Kun-Huei Yeh
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 10, Pp 2057-2064 (2022)
Background: Ramucirumab is indicated for salvage treatment after failure of first-line treatment for metastatic colorectal cancer (mCRC). However, the application of ramucirumab at later-line treatment in real-world practice has not received much dis
Externí odkaz:
https://doaj.org/article/827a6da68f80450285f215c0d9aebce3
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 1, Pp 447-454 (2022)
Colorectal cancer (CRC) in pregnancy is rare and often presents at a late stage due to the masking of signs by pregnancy. A typical chemotherapeutic regimen for stage III and IV CRC comprised 5-Fluorouracil (5-FU) and oxaliplatin. The treatment of CR
Externí odkaz:
https://doaj.org/article/347778a0082c4f86871b338309c5f90f
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 6, Iss 1, Pp 24-31 (2022)
Objectives: This retrospective study explored the feasibility of neoadjuvant chemotherapy (NAC) without radiotherapy in patients with locally advanced rectal cancer (LARC). Methods: Patients with clinical stage of T3-T4 and/or N-positive LARC patient
Externí odkaz:
https://doaj.org/article/667649c228794d53a6caba459c16c958
Autor:
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, Cristiano Felicetti, Lisa Salvatore, Maria Bensi, Maria Grazia Maratta, Antonia Strippoli, Roberto Filippi, Maria Antonietta Satolli, Angelica Petrillo, Bruno Daniele, Michele De Tursi, Pietro Di Marino, Guido Giordano, Matteo Landriscina, Pasquale Vitale, Ina Valeria Zurlo, Emanuela Dell’Aquila, Silverio Tomao, Ilaria Depetris, Francesca Romana Di Pietro, Federica Zoratto, Davide Ciardiello, Maria Vittoria Pensieri, Ornella Garrone, Barbara Galassi, Claudio Ferri, Rossana Berardi, Michele Ghidini
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AimThe aim of the current study is to investigate the impact of primary compared to secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients affected by gastrointestinal malignancies and
Externí odkaz:
https://doaj.org/article/a870c172dbe94deaa83affaa21374c17
Autor:
M. Yu. Fedyanin, E. M. Polyanskaya, H. H.-M. Elsnukaeva, A. A. Tryakin, I. A. Pokataev, A. A. Bulanov, S. A. Tjulandin
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 125-132 (2020)
Introduction. Based on the subgroup analysis of the TRIBE study FOLFOXIRI with bevacizumab is the recommended option for patients (pts) with mBRAF metastatic colorectal cancer (mCRC) in the 1st line. However, subgroup analysis of other studies showed
Externí odkaz:
https://doaj.org/article/ee57e07abaa94e0ca701173d11ac940a
Autor:
Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combin
Externí odkaz:
https://doaj.org/article/c60e1d3ac27b4918a6f12db6c2a7c54a
Autor:
Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Francesco Iachetta, Alessandra Romagnani, Erika Gervasi, Mario Larocca, Carmine Pinto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The NIVACOR trial is a phase II study assessing the efficacy and safety of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line setting in patients affected by metastatic colorectal cancer (mCRC) RAS/BRAF mutated. We report safety run-in
Externí odkaz:
https://doaj.org/article/1889dd61354f4db5bf652ae999580102